medigraphic.com
ISSN 1027-2852 (Digital)
ISSN 0864-4551 (Impreso)

2013, Número 4

<< Anterior Siguiente >>

Biotecnol Apl 2013; 30 (4)


Identificación de la primera molécula peptídica que inhibe efectos biológicos de la interleucina-15

Santos A, Reyes O, Cabrales A, Rodríguez Y, Geronimo H, Garay HE, Arrieta CA, Ojeda M, Machado AC, Suarez J, Ancisar JA, Vázquez M, Guillén G, Chico A, Estévez M, Llopiz A, Noda J, Sánchez A, Silengo L, Altruda F, Perea S

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 317-319
Archivo PDF: 197.62 Kb.


RESUMEN

La interleucina-15 (IL-15) es una citocina proinflamatoria que se expresa en varias enfermedades autoinmunes e inflamatorias. Se identificó la secuencia 36-45 KVTAMKCFLL de la IL-15 humana, reconocida por la proteína de fusión hIL-15Rα-Fc soluble. Esta secuencia, sintetizada como un péptido de 10 aminoácidos, se une a la IL-15Rα y bloquea la actividad biológica de la IL-15 en dos líneas celulares dependientes de IL-15. Mediante la estrategia de barrido de Ala, se detectó un péptido más activo por sustitución de la segunda lisina de la secuencia del péptido por el aminoácido polar, no cargado, treonina. Usando el péptido P8 en el paso de captura de un ensayo por inmunoabsorción ligado a enzimas (ELISA), recientemente desarrollado, se cuantificó IL-15Rα soluble en fluido sinovial de pacientes con artritis reumatoide (AR) u osteoartritis (OA). Este trabajo mereció el Premio Anual de la Academia de Ciencias de Cuba, en el año 2012.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429-42.

  2. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009;11 Suppl 1:S1.

  3. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000;51:207-29.

  4. McInnes IB, Liew FY. Cytokine networks- towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2005;1(1):31-9.

  5. McInnes IB, al-Mughales J, Field M, Leung BP, Huang FP, Dixon R, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med. 1996;2(2):175-82.

  6. Carroll HP, Paunovic V, Gadina M. Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity. Rheumatology (Oxford). 2008;47(9):1269-77.

  7. McInnes IB, Gracie JA, Harnett M, Harnett W, Liew FY. New strategies to control infl ammatory synovitis: interleukin 15 and beyond. Ann Rheum Dis. 2003;62 Suppl 2:ii51-4.

  8. Oppenheimer-Marks N, Brezinschek RI, Mohamadzadeh M, Vita R, Lipsky PE. Interleukin 15 is produced by endothelial cells and increases the transendothelial migration of T cells In vitro and in the SCID mouse-human rheumatoid arthritis model In vivo. J Clin Invest. 1998;101(6):1261-72.

  9. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T celldependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med. 1997;3(2):189-95.

  10. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifi lieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol. 2003;170(4):2106-12.

  11. Verri WA Jr, Cunha TM, Ferreira SH, Wei X, Leung BP, Fraser A, et al. IL-15 mediates antigen-induced neutrophil migration by triggering IL-18 production. Eur J Immunol. 2007;37(12):3373-80.

  12. Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, Miyazaki S, et al. A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol. 1999;162(5):2754-60.

  13. Miranda-Carus ME, Benito-Miguel M, Balsa A, Cobo-Ibanez T, Perez de Ayala C, Pascual-Salcedo D, et al. Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum. 2006;54(4):1151-64.

  14. Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem. 2004;279(40):42192-201.

  15. Neely GG, Epelman S, Ma LL, Colarusso P, Howlett CJ, Amankwah EK, et al. Monocyte surface- bound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol. 2004;172(7):4225-34.

  16. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity. 2002;17(5):537-47.

  17. Baslund B, Tvede N, Danneskiold-Samsoe B, Petersen J, Petersen LJ, Schuurman J, et al. A novel human monoclonal antibody against IL-15 (humax-IL15) in patients with active rheumatoid arthritis (RA): results of a doubleblind, placebocontrolled phase I/II trial. Arthritis Rheum. 2003;48 Suppl 9:S1706.

  18. Kim YS, Maslinski W, Zheng XX, Stevens AC, Li XC, Tesch GH, et al. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayedtype hypersensitivity. J Immunol. 1998; 160(12):5742-8.

  19. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY. Soluble IL-15 receptor alpha-chain administration prevents murine collageninduced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol. 1998;160(11):5654-60.

  20. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, et al. Converting IL-15 to a superagonist by binding to soluble IL-15Ralpha. Proc Natl Acad Sci USA. 2006;103(24):9166-71.

  21. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, et al. Soluble interleukin- 15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem. 2006;281(3):1612-9.

  22. Santos A, Cabrales A, Reyes O, Gerónimo H, Rodríguez Y, Garay H, Arrieta C, Silva R, Guillen G. Identifi cation of an interleukin-15 antagonist peptide that binds to IL-15Rα. Biotecnol Apl. 2008;25(4):320-4.

  23. Savio AS, Acosta OR, Perez HG, Alvarez YR, Chico A, Ojeda MO, et al. Enhancement of the inhibitory effect of an IL-15 antagonist peptide by alanine scanning. J Pept Sci. 2012; 18(1):25-9.

  24. Machado Diaz AC, Chico Capote A, Arrieta Aguero CA, Rodriguez Alvarez Y, Garcia Del Barco Herrera D, Estevez Del Toro M, et al. Proinfl ammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis. Arthritis. 2012;2012:943156.




2020     |     www.medigraphic.com